WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205928
Description: Pivanex, also known as AN-9, is a histone deacetylase inhibitor analog of butyric acid that causes apoptosis of cancer cells through signaling cellular differentiation. AN-9 exerts a significant anticancer activity in vitro and in vivo.
MedKoo Cat#: 205928
Chemical Formula: C10H18O4
Exact Mass: 202.12051
Molecular Weight: 202.25
Elemental Analysis: C, 59.39; H, 8.97; O, 31.64
Synonym: Pivanex, AN9, pivaloyloxymethyl butyrate, Titan.
IUPAC/Chemical Name: (pivaloyloxy)methyl butyrate
InChi Key: GYKLFBYWXZYSOW-UHFFFAOYSA-N
InChi Code: InChI=1S/C10H18O4/c1-5-6-8(11)13-7-14-9(12)10(2,3)4/h5-7H2,1-4H3
SMILES Code: CCCC(OCOC(C(C)(C)C)=O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >5 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 202.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Rabizadeh E, Shaklai M, Eisenbach L, Nudelman A, Rephaeli A. Esterase inhibitors diminish the modulation of gene expression by butyric acid derivative, pivaloyloxymethyl butyrate (AN-9). Isr J Med Sci. 1996 Dec;32(12):1186-91. PubMed PMID: 9007151.
2: Zimra Y, Wasserman L, Maron L, Shaklai M, Nudelman A, Rephaeli A. Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. J Cancer Res Clin Oncol. 1997;123(3):152-60. PubMed PMID: 9119880.
3: Cutts SM, Rephaeli A, Nudelman A, Hmelnitsky I, Phillips DR. Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9). Cancer Res. 2001 Nov 15;61(22):8194-202. PubMed PMID: 11719450.
4: Hobdy E, Murren J. AN-9 (Titan). Curr Opin Investig Drugs. 2004 Jun;5(6):628-34. Review. PubMed PMID: 15242252.
5: Reid T, Valone F, Lipera W, Irwin D, Paroly W, Natale R, Sreedharan S, Keer H, Lum B, Scappaticci F, Bhatnagar A. Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer. Lung Cancer. 2004 Sep;45(3):381-6. PubMed PMID: 15301879.
6: Blank-Porat D, Gruss-Fischer T, Tarasenko N, Malik Z, Nudelman A, Rephaeli A. The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties. Cancer Lett. 2007 Oct 18;256(1):39-48. Epub 2007 Jul 3. PubMed PMID: 17611019.
7: Tarasenko N, Nudelman A, Tarasenko I, Entin-Meer M, Hass-Kogan D, Inbal A, Rephaeli A. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin Exp Metastasis. 2008;25(7):703-16. doi: 10.1007/s10585-008-9179-x. Epub 2008 May 28. PubMed PMID: 18506586.